The results of a multicenter retrospective controlled clinical study of the efficacy and safety of L-lysine aescinate® in the treatment of traumatic and postoperative cerebral edema

Authors

  • Yu.Yu. Kobeliatskyi State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Municipal Enterprise “Volyn Regional Clinical Hospital”, Lutsk, Ukraine; Municipal Non-Profit Enterprise “Lviv Clinical Emergency Hospital”, Lviv, Ukraine; Regional Municipal Non-Profit Enterprise “Chernivtsi Regional Emergency Hospital”, Chernivtsi, Ukraine; Municipal Non-Profit Enterprise “City Emergency Hospital” of Zaporizhzhia City Council, Zaporizhzhia, Ukraine
  • I.S. Bobryk State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Municipal Enterprise “Volyn Regional Clinical Hospital”, Lutsk, Ukraine; Municipal Non-Profit Enterprise “Lviv Clinical Emergency Hospital”, Lviv, Ukraine; Regional Municipal Non-Profit Enterprise “Chernivtsi Regional Emergency Hospital”, Chernivtsi, Ukraine; Municipal Non-Profit Enterprise “City Emergency Hospital” of Zaporizhzhia City Council, Zaporizhzhia, Ukraine
  • A.M. Netliukh State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Municipal Enterprise “Volyn Regional Clinical Hospital”, Lutsk, Ukraine; Municipal Non-Profit Enterprise “Lviv Clinical Emergency Hospital”, Lviv, Ukraine; Regional Municipal Non-Profit Enterprise “Chernivtsi Regional Emergency Hospital”, Chernivtsi, Ukraine; Municipal Non-Profit Enterprise “City Emergency Hospital” of Zaporizhzhia City Council, Zaporizhzhia, Ukraine
  • I.I. Ilashchuk State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Municipal Enterprise “Volyn Regional Clinical Hospital”, Lutsk, Ukraine; Municipal Non-Profit Enterprise “Lviv Clinical Emergency Hospital”, Lviv, Ukraine; Regional Municipal Non-Profit Enterprise “Chernivtsi Regional Emergency Hospital”, Chernivtsi, Ukraine; Municipal Non-Profit Enterprise “City Emergency Hospital” of Zaporizhzhia City Council, Zaporizhzhia, Ukraine
  • D.S. Ivakhnenko State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine; Municipal Enterprise “Volyn Regional Clinical Hospital”, Lutsk, Ukraine; Municipal Non-Profit Enterprise “Lviv Clinical Emergency Hospital”, Lviv, Ukraine; Regional Municipal Non-Profit Enterprise “Chernivtsi Regional Emergency Hospital”, Chernivtsi, Ukraine; Municipal Non-Profit Enterprise “City Emergency Hospital” of Zaporizhzhia City Council, Zaporizhzhia, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.8.2020.221957

Keywords:

severe traumatic brain injury, cerebral edema, intracranial pressure, intracranial hypertension, L-lysine aescinate®

Abstract

In modern guidelines, the control of intracranial pressure is recognized as an important prerequisite for quality reco-very of brain functions after severe traumatic brain injury (TBI). Among the relatively new approaches to the control of intracranial pressure in severe TBI, a combination drug L-lysine aescinate® is considered. It has endotheliotropic, venotonic, anti-inflammatory, antiplatelet and other effects that allow it to be regarded as a mean for preventing and reducing cerebral edema after TBI. To evaluate the efficacy and effects of L-lysine aescinate®, a multicenter retrospective study was conducted that included 988 patients aged 18 to 65 years with isolated or combined severe or moderate TBI. The median injury severity index was 17 points, i.e. most people had a serious injury. Patients were randomized into two groups, one of which (n = 335) received only standard therapy, while the other (n = 653) — additionally L-lysine aescinate®. L-lysine aescinate® was prescribed on the first day of hospitalization (median — 2.75 hours) and for a course of 2 to 8 days (median — 7 days). Mortality in the intensive care unit (primary endpoint) was 10.3 and 24.2 % in the main and control groups, respectively (difference 13.9 %; 95% confidence interval (CI): 8.93–19.21 %; p < 0.001). Logistic regression method revealed that L-lysine aescinate® was the most important factor influencing patient survival (p < 0.001). Its use increased the chances of survival of a patient with TBI in the intensive care unit by 3.3 times (odds ratio (OR) = 3.311; 95% CI: 2.108–5.200). Similar results were obtained for 30-day hospital mortality. The frequency of recovery of clear consciousness during the hospital stay was 87.0 % in the group of L-lysine aescinate® and 66.0 % in the control group, with a significant difference between them (p < 0.001). Administration of L-lysine aescinate® increased the chances for restoring clear consciousness in a patient with TBI by 3.8 times (OR = 3.823; 95% CI: 2.535–5.765). The results of the study allow us to recommend the inclusion of L-lysine aescinate® in the standard therapy of patients with isolated or combined severe or moderate TBI.

Downloads

Download data is not yet available.

References

Brain Trauma Foundation (USA). Guidelines for the Management of Severe Traumatic Brain Injury. https://braintrauma.org/uploads/13/06/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf.

Brain Trauma Foundation. Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations.

American College of Surgeons. ACS TQIP Best Practices in the management of traumatic brain injury. https://academic.oup.com/neurosurgery/article/87/3/427/5881627.

World Society of Emergency Surgery. WSES consensus confe-rence guidelines: monitoring and management of severe adult trauma-tic brain injury patients with polytrauma in the first 24 hours. https://www.facs.org/-/media/files/quality-programs/trauma/tqip/tbi_guidelines.ashx.

CDC and the American College of Emergency Physicians. Updated Mild Traumatic Brain Injury Guideline for Adults. https://wjes.biomedcentral.com/articles/10.1186/s13017-019-0270-1.

European Brain Injury Consortium. EBIC-guidelines for ma-nagement of severe head injury in adults. https://www.cdc.gov/trauma-ticbraininjury/pdf/TBI_Clinicians_Factsheet-a.pdf.

Canadian Family Physician. Clinical practice guidelines for mild traumatic brain injury and persistent symptoms. https://core.ac.uk/download/pdf/187926379.pdf.

French Society of Anesthesia and Intensive Care Medicine. Management of severe traumatic brain injury (first 24 hours). http://europepmc.org/article/PMC/3303645.

https://www.sciencedirect.com/science/article/pii/S2352556817303703.

Chesnut R.M. et al. A Method of Managing Severe Traumatic Brain Injury in the Absence of Intracranial Pressure Monitoring: The Imaging and Clinical Examination Protocol. J. Neurotrauma. 2018 Jan 1. 35(1). 54-63.

Fleiss J.L. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.

Conover W.J., Iman R.L. Rank transformations as a bridge between parametric and nonparametric statistics. American Statistician. 1981. 35. 124-129.

Лапач С.Н., Чубенко А.В., Бабич П.Н. Статистика в науке и бизнесе. К.: Морион, 2002. 640 с.

Published

2021-11-15

How to Cite

Kobeliatskyi, Y., Bobryk, I., Netliukh, A., Ilashchuk, I., & Ivakhnenko, D. (2021). The results of a multicenter retrospective controlled clinical study of the efficacy and safety of L-lysine aescinate® in the treatment of traumatic and postoperative cerebral edema. INTERNATIONAL NEUROLOGICAL JOURNAL, 16(8), 21–32. https://doi.org/10.22141/2224-0713.16.8.2020.221957

Issue

Section

Original Researches